Operation Warp Speed’s seal was a combination of ’70s design, au courant clip art, and 18th Century militarism, but just like the oddly assembled organization that it represented, the thing worked.
Operation Warp Speed has not been called “Operation Warp Speed” since the beginning of the Biden administration, but as the one-year anniversary of the authorization of the first COVID-19 vaccine approaches, In Vivo is reflecting on what is widely considered the most effective aspects of the US government’s pandemic response.
Launched by the Trump administration as an effort to collaborate with private industry to develop vaccines, diagnostics and therapeutics in...
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
